v3.25.2
Collaboration, License, and Supply Agreements - Sanofi (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Current deferred revenue $ 113,763   $ 113,763   $ 675,067
Noncurrent deferred revenue 399,263   399,263   $ 446,819
Total revenue 239,240 $ 415,484 905,895 $ 509,339  
Sanofi          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Development, tech transfer, launch, and sales milestone payments 700,000        
Sanofi | Selling, general, and administrative          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Capitalized contract cost, amortization 900 27,100 1,800    
Licensed COVID-19 products and royalty payments | Sanofi          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Development, tech transfer, launch, and sales milestone payments 475,000        
Transfer of approval of marketing authorization for the COVID-19 vaccine from the FDA | Sanofi          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Development, tech transfer, launch, and sales milestone payments 25,000        
Transfer of EMA approval of the COVID-19 vaccine | Sanofi          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Development, tech transfer, launch, and sales milestone payments 25,000        
Completion of the technology transfer of the Company’s manufacturing process for the COVID-19 Vaccine | Sanofi          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Development, tech transfer, launch, and sales milestone payments 75,000        
CIC Product-Related Development Milestones | Sanofi          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Development, tech transfer, launch, and sales milestone payments 125,000        
CIC Product-Related Launch Milestones | Sanofi          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Development, tech transfer, launch, and sales milestone payments 225,000        
Database lock of an Existing Phase 2/3 clinical trial          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Development, tech transfer, launch, and sales milestone payments 50,000        
First Four Adjuvant Products | Sanofi          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Development, tech transfer, launch, and sales milestone payments 200,000        
Adjuvant Products Thereafter | Sanofi          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Development, tech transfer, launch, and sales milestone payments 210,000        
Transition Services | Sanofi          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total licensing, royalties, and other revenue 24,400 6,600 64,700 6,600  
Deferred revenue 42,700   42,700    
Current deferred revenue 32,000   32,000    
Noncurrent deferred revenue 10,700   10,700    
Cumulative catch up adjustment (1,500)   8,700    
Product and Service, Other | Sanofi          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Capitalized contract cost, amortization     35,000    
Licensing, royalties, and other          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Total revenue $ 228,516 $ 392,896 $ 273,493 $ 396,915